Bremner D A
Department of Immunobiology, School of Medicine, University of Auckland.
Pathology. 1987 Jul;19(3):274-6. doi: 10.3109/00313028709066562.
The in-vitro activity of ceftazidime was compared with other third-generation cephalosporins and gentamicin against 409 isolates. Ceftazidime was the most active agent against Enterobacter sp., Proteus mirabilis, Serratia sp., Proteus sp. and Pseudomonas aeruginosa. It was less active against Escherichia coli and Klebsiella than moxalactam and cefotaxime but more active than cefoperazone. Against gentamicin resistant E. coli, Klebsiella, Enterobacter and P. aeruginosa, ceftazidime was more active than moxalactam, cefotaxime or cefoperazone but was as active as moxalactam against gentamicin-resistant Proteus sp. and more active than cefotaxime and cefoperazone.
将头孢他啶的体外活性与其他第三代头孢菌素及庆大霉素针对409株分离菌进行了比较。头孢他啶是针对肠杆菌属、奇异变形杆菌、沙雷菌属、变形杆菌属和铜绿假单胞菌最具活性的药物。它对大肠杆菌和克雷伯菌的活性低于拉氧头孢和头孢噻肟,但高于头孢哌酮。针对对庆大霉素耐药的大肠杆菌、克雷伯菌、肠杆菌和铜绿假单胞菌,头孢他啶比拉氧头孢、头孢噻肟或头孢哌酮更具活性,但针对对庆大霉素耐药的变形杆菌属时,其活性与拉氧头孢相当,且比头孢噻肟和头孢哌酮更具活性。